Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme IncfiledCriticalEpizyme Inc
Priority claimed from PCT/US2013/077235external-prioritypatent/WO2014100719A2/en
Publication of MA38280A1publicationCriticalpatent/MA38280A1/en
Publication of MA38280B1publicationCriticalpatent/MA38280B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
L'invention concerne des composés de formule (a), des sels pharmaceutiquement acceptables de ceux-ci et des compositions pharmaceutiques de ceux-ci. Les composés de la présente invention sont utiles pour inhiber l'activité de prmt5. L'invention concerne également des procédés d'utilisation de composés pour le traitement de troubles médiés par prmt5.The invention relates to compounds of formula (a), pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof. The compounds of the present invention are useful for inhibiting prmt5 activity. The invention also relates to methods of using compounds for the treatment of prmt5 mediated disorders.
MA38280A2012-12-212013-12-20
Substituted 1,2,3,4-tetrahydroisoquinoline compounds inhibiting arginine-methyltransferase protein 5
MA38280B1
(en)
1H-indazole-3-carboxamide derivatives and related compounds as factor D inhibitors for treating diseases characterized by aberrant complement system activity, such as e.g. immunological disorders